The clinical and nonclinical safety record was subsequently marshaled in support of a Generally Recognized as Safe (GRAS) determination for AOD9604 as a dietary ingredient, conditional on publication of the underlying safety data [7]
3 Given the normal BMO diameter, the absence of other systemic predisposing conditions, such as hypertension, diabetes mellitus, and hypercoagulability, and the temporal relationship between the drugs intake and the ocular disease, a plausible association between GLP-1 RAs administration and NAION may be considered in our case
BPC-157s human trials were early-phase IBD
Such a setup would precisely delineate the NSC-derived paracrine factors (e.g., BDNF, VEGF [18, 32], TGF-) responsible for suppressing microglial activation and promoting an anti-inflammatory phenotype, independently of in vivo complexities
Alexiou et al
Yale is a Wilson Disease Center of Excellence